Somatropin (Y-shaped pegylation) - Xiamen Amoytop Biotech

Drug Profile

Somatropin (Y-shaped pegylation) - Xiamen Amoytop Biotech

Alternative Names: Y-Pegylated somatropin - Xiamen Amoytop Biotech; YPEG-rhGH; YPEG-somatropin - Xiamen Amoytop Biotech

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Somatotropin deficiency

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Somatotropin-deficiency(In volunteers) in China (SC, Injection)
  • 16 Jul 2013 Biomarkers information updated
  • 31 Aug 2012 Xiamen Amoytop Biotech completes a phase I trial in Healthy volunteers in China (NCT01339182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top